Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


August 29, 2015 11:50 AM ET

Biotechnology

Company Overview of Celgene Cellular Therapeutics

Company Overview

Celgene Cellular Therapeutics engages in the research, recovery culture-expansion, preservation, development, and distribution of placental cells. The company develops placental cells, including stem and progenitor cells as therapeutic agents. It discovers and develops therapeutics from cells derived from the human placenta, as well as from the umbilical cord. The company develops stem cells for therapeutic applications in cancer, as well as autoimmune, cardiovascular, neurological, and degenerative diseases. It also operates a private umbilical cord blood bank. The company was formerly known as Anthrogenesis Corp. and changed its name to Celgene Cellular Therapeutics in 2002. Celgene Cellul...

7 Powder Horn Drive

Warren, NJ 07059-5190

United States

Phone:

908-673-9000

Fax:

908-673-9001

Key Executives for Celgene Cellular Therapeutics

Celgene Cellular Therapeutics does not have any Key Executives recorded.

Celgene Cellular Therapeutics Key Developments

BioCision, LLC to Develop Customized ThawSTAR Automated Cell Thawing System for Celgene Cellular Therapeutics

BioCision, LLC announced that it will collaborate with Celgene Cellular Therapeutics (CCT) to accelerate the development of a cell thawing solution based on BioCision's proprietary ThawSTAR™ technology for the 6 mL injectable vial that CCT has chosen to store PDA-002, a cryopreserved, allogeneic cell therapy currently in clinical development to treat diabetic foot ulcers in patients with peripheral arterial disease. Conventional thawing methods, including swirling vials in warm water baths or rolling vials between hands can result in variable cell viabilities and can increase contamination concerns. BioCision’s ThawSTAR system utilizes a patent pending adaptive sensing technology that incorporates algorithms to deliver a consistent and reproducible thaw profile and endpoint to each vial, thus providing a standardized thawing process, eliminating variability that could have a detrimental effect on the safety and efficacy of the cell therapy, and providing a significant reduction in cell handling risk in a clinical setting. The new ThawSTAR automated cell thawing system that will be developed as a result of this collaboration is an expansion of BioCision’s technology platform and will be made available commercially. BioCision is also developing other vial formats to address the needs of the larger cell therapy market.

Alliqua Biomedical Amends Exclusive Licensing Agreement with Celgene Cellular Therapeutics

Alliqua Biomedical announced that it has amended its exclusive licensing agreement with Celgene Cellular Therapeutics (CCT), in the advanced tissue market. This amended agreement provides Alliqua with the right to develop and market CCT's connective tissue matrix product (CTM). Celgene Cellular Therapeutics' CTM product is derived from human placental tissue and will be launched by Alliqua upon commercialiasation. The CTM product is the third tissue product Alliqua has licensed from Celgene, following Biovance, Human Amniotic Membrane Allograft and Placental Extra Cellular Matrix, also in development. Alliqua plans to launch connective tissue matrix mid 2016 to compete in the approximately USD 660 million advanced tissue market, along with its Biovance Human Amniotic Membrane Allograft, the first product introduced through its Celgene partnership in 2014.

Alliqua Amends Licensing Agreement with Celgene Cellular Therapeutics to Market Biovance

Alliqua announced that it has amended a licensing agreement with Celgene Cellular Therapeutics, giving Aliqua the right to market advanced wound care product Biovance for podiatric and orthopedic applications. Biovance is a drug used to manage non-infected wounds including chronic and acute diabetic, pressure, venous and chronic vascular ulcers, and surgical and trauma woulds such as abrasions, lacerations and second-degree burns. Podiatrists use Biovance for sports medicine purposes.

Similar Private Companies By Industry

Company Name Region
SKS Ocular, LLC United States
Genomic Expression Inc. United States
Novartis Animal Vaccines, Inc United States
Elusys Therapeutics, Inc. United States
CLINIQA Corporation United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Celgene Cellular Therapeutics, please visit www.celgene.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.